ERK/MAPK signalling pathway and tumorigenesis
YJ Guo, WW Pan, SB Liu… - Experimental and …, 2020 - spandidos-publications.com
Mitogen-activated protein kinase (MAPK) cascades are key signalling pathways that
regulate a wide variety of cellular processes, including proliferation, differentiation …
regulate a wide variety of cellular processes, including proliferation, differentiation …
The MAPK pathway across different malignancies: a new perspective
M Burotto, VL Chiou, JM Lee, EC Kohn - Cancer, 2014 - Wiley Online Library
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway
is activated by upstream genomic events and/or activation of multiple signaling events in …
is activated by upstream genomic events and/or activation of multiple signaling events in …
The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults
KN Patel, L Yip, CC Lubitz, EG Grubbs, BS Miller… - Annals of …, 2020 - journals.lww.com
Objective: To develop evidence-based recommendations for safe, effective, and appropriate
thyroidectomy. Background: Surgical management of thyroid disease has evolved …
thyroidectomy. Background: Surgical management of thyroid disease has evolved …
Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study
JD Hainsworth, F Meric-Bernstam… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Detection of specific molecular alterations in tumors guides the selection of
effective targeted treatment of patients with several types of cancer. These molecular …
effective targeted treatment of patients with several types of cancer. These molecular …
Integrated genomic characterization of papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …
2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association …
BR Haugen, EK Alexander, KC Bible, GM Doherty… - Thyroid, 2016 - liebertpub.com
Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …
BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence
Purpose To investigate the prognostic value of the BRAF V600E mutation and the recently
identified TERT promoter mutation chr5: 1,295,228 C> T (C228T), individually and in their …
identified TERT promoter mutation chr5: 1,295,228 C> T (C228T), individually and in their …
Epidemiology of thyroid cancer
CM Kitahara, AB Schneider - Cancer epidemiology, biomarkers & prevention, 2022 - AACR
Background The incidence of thyroid cancer has risen dramatically in the United States over
the past four decades, with similar patterns observed internationally. Thyroid cancer …
the past four decades, with similar patterns observed internationally. Thyroid cancer …
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
M Xing, AS Alzahrani, KA Carson, YK Shong… - Journal of clinical …, 2015 - ascopubs.org
Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre …
MS Brose, ME Cabanillas, EEW Cohen, LJ Wirth… - The lancet …, 2016 - thelancet.com
Background About half of patients with papillary thyroid cancer have tumours with activating
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …